drugset / Trial / NCT01363947
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study DNB4987g is a Phase I, multicenter, open label, dose-escalation study of DNIB0600A administered as a single agent by intravenous (IV) infusion every three weeks (q3w) to participants with non-squamous NSCLC or non-mucinous, platinum-resistant ovarian cancer. The study will be conducted in two cohorts: Dose-escalation cohort and Expansion cohort.
Timeline
- Start
- 2011-06-14
- Primary completion
- 2016-06-03
- Completion
- 2016-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lifastuzumab vedotin | Unknown | 0.2 mg/kg | Intravenous |
| Subject | Lifastuzumab vedotin | Unknown | 2.4 mg/kg | Intravenous |
| Subject | Lifastuzumab vedotin | Unknown | 2.8 mg/kg | Intravenous |